Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in <i>db/db</i> Mice Using Cytokine Antibody Array

<div class="floats-full-page floats-full-page-other"><h2>Table 3</h2><div class="floats-full-page-caption"><div>The relative expression changes of 29 cytokines.</div></div><div class="floats-full-page-content"><table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr /></td></tr><tr class="thead"><td class="align_left">Number</td><td class="align_center">Cytokines</td><td class="align_center">Model group (expt. week 12)/model group (expt. week 0)</td><td class="align_center">LST group (expt. week 12)/model group (expt. week 0)</td><td class="align_center">TSF group (expt. week 12)/model group (expt. week 0)</td></tr><tr><td class="thead-hr" colspan="5"><hr /></td></tr><tr><td class="align_left">1</td><td class="align_center">VEGF</td><td class="align_center">0.94</td><td class="align_center">0.97</td><td class="align_center">0.75</td></tr><tr><td class="align_left">2</td><td class="align_center">VEGF R2</td><td class="align_center">0.90</td><td class="align_center">1.48</td><td class="align_center">0.64</td></tr><tr><td class="align_left">3</td><td class="align_center">IGFBP-3</td><td class="align_center">1.13</td><td class="align_center">1.05</td><td class="align_center">0.96</td></tr><tr><td class="align_left">4</td><td class="align_center">SCF</td><td class="align_center">0.95</td><td class="align_center">1.00</td><td class="align_center">0.67</td></tr><tr><td class="align_left">5</td><td class="align_center">IL-2</td><td class="align_center">1.52</td><td class="align_center">1.47</td><td class="align_center">1.01</td></tr><tr><td class="align_left">6</td><td class="align_center">IL-4</td><td class="align_center">3.72</td><td class="align_center">3.73</td><td class="align_center">2.02</td></tr><tr><td class="align_left">7</td><td class="align_center">IL-6</td><td class="align_center">1.61</td><td class="align_center">1.26</td><td class="align_center">1.32</td></tr><tr><td class="align_left">8</td><td class="align_center">IL-13</td><td class="align_center">1.19</td><td class="align_center">1.14</td><td class="align_center">0.96</td></tr><tr><td class="align_left">9</td><td class="align_center">IL-15</td><td class="align_center">1.05</td><td class="align_center">0.82</td><td class="align_center">0.83</td></tr><tr><td class="align_left">10</td><td class="align_center">FAS ligand</td><td class="align_center">0.99</td><td class="align_center">0.78</td><td class="align_center">0.65</td></tr><tr><td class="align_left">11</td><td class="align_center">ICAM-1</td><td class="align_center">0.54</td><td class="align_center">0.69</td><td class="align_center">0.42</td></tr><tr><td class="align_left">12</td><td class="align_center">VCAM-1</td><td class="align_center">0.35</td><td class="align_center">0.42</td><td class="align_center">0.24</td></tr><tr><td class="align_left">13</td><td class="align_center">PF4</td><td class="align_center">0.93</td><td class="align_center">0.67</td><td class="align_center">0.56</td></tr><tr><td class="align_left">14</td><td class="align_center">TIMP-1</td><td class="align_center">0.99</td><td class="align_center">1.05</td><td class="align_center">0.73</td></tr><tr><td class="align_left">15</td><td class="align_center">IFN-gamma</td><td class="align_center">1.76</td><td class="align_center">1.70</td><td class="align_center">1.51</td></tr><tr><td class="align_left">16</td><td class="align_center">Decorin</td><td class="align_center">2.02</td><td class="align_center">1.88</td><td class="align_center">1.56</td></tr><tr><td class="align_left">17</td><td class="align_center">TNF-alpha</td><td class="align_center">1.50</td><td class="align_center">1.26</td><td class="align_center">1.27</td></tr><tr><td class="align_left">18</td><td class="align_center">IL-3</td><td class="align_center">0.76</td><td class="align_center">0.68</td><td class="align_center">0.51</td></tr><tr><td class="align_left">19</td><td class="align_center">IL-7</td><td class="align_center">1.37</td><td class="align_center">1.18</td><td class="align_center">1.01</td></tr><tr><td class="align_left">20</td><td class="align_center">IL-10</td><td class="align_center">0.74</td><td class="align_center">0.63</td><td class="align_center">0.59</td></tr><tr><td class="align_left">21</td><td class="align_center">IL-17</td><td class="align_center">0.74</td><td class="align_center">0.65</td><td class="align_center">0.54</td></tr><tr><td class="align_left">22</td><td class="align_center">MCP-1</td><td class="align_center">0.64</td><td class="align_center">0.59</td><td class="align_center">0.41</td></tr><tr><td class="align_left">23</td><td class="align_center">M-CSF</td><td class="align_center">0.70</td><td class="align_center">0.64</td><td class="align_center">0.53</td></tr><tr><td class="align_left">24</td><td class="align_center">CD36</td><td class="align_center">0.74</td><td class="align_center">0.63</td><td class="align_center">0.49</td></tr><tr><td class="align_left">25</td><td class="align_center">EGF</td><td class="align_center">0.59</td><td class="align_center">0.36</td><td class="align_center">0.75</td></tr><tr><td class="align_left">26</td><td class="align_center">IGFBP-2</td><td class="align_center">0.74</td><td class="align_center">0.65</td><td class="align_center">0.98</td></tr><tr><td class="align_left">27</td><td class="align_center">IGF-II</td><td class="align_center">0.64</td><td class="align_center">0.59</td><td class="align_center">0.86</td></tr><tr><td class="align_left">28</td><td class="align_center">MMP-2</td><td class="align_center">0.70</td><td class="align_center">0.64</td><td class="align_center">0.95</td></tr><tr><td class="align_left">29</td><td class="align_center">E-cadherin</td><td class="align_center">1.05</td><td class="align_center">1.01</td><td class="align_center">1.23</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr" /></td></tr></table></td></tr></table></div></div>

Table 3 | Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in <i>db/db</i> Mice Using Cytokine Antibody Array

title

Table 3: Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in <i>db/db</i> Mice Using Cytokine Antibody Array

description

Table 3 | Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in db/db Mice Using Cytokine Antibody Array

Table 3

About this journal

<p><em>Journal of Diabetes Research</em> publishes articles related to type 1 and type 2 diabetes. Topics include etiology, pathogenesis, management, and prevention of diabetes, as well as associated complications such as nephropathy.</p>


Journal profile

Meet the editorial board

<p>Chief Editor Dr Mark Yorek, from the University of Iowa, is currently researching vascular and neural disease related to obesity and diabetes. His active research studies focus on etiology, treatment and prevention of nerve damage.</p>


Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.